NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Up 1.7 %

Shares of NYSE NBY opened at $0.58 on Friday. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The business has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.62. The firm has a market cap of $3.37 million, a PE ratio of -0.01 and a beta of 0.90.

Insider Buying and Selling

In other news, major shareholder Poplar Point Capital Partners purchased 70,685 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $45,945.25. Following the completion of the purchase, the insider now owns 620,685 shares of the company’s stock, valued at approximately $403,445.25. This trade represents a 12.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders purchased 301,077 shares of company stock worth $188,978. Insiders own 0.10% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.